



First Quarter 2023 Results

May 4, 2023

enovis™

Creating Better Together™

Forward-looking Statements

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis' plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis' current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis' results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic; the war in Ukraine and escalating geopolitical tensions as a result of Russia's invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; the impacts of the recently completed spin-off of ESAB Corporation into an independent publicly traded company (the "Separation") the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation, the financial and operating performance of the Company following the Separation; other impacts on Enovis' business and ability to execute business continuity plans; and the other factors detailed in Enovis' reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in Enovis' filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Non-GAAP Financial Information

Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin and organic sales growth. Adjusted net income from continuing operations and adjusted net income per diluted share from continuing operations exclude restructuring and other charges, European Union Medical Device Regulation ("MDR") and other costs, amortization of acquired intangibles, inventory step-up costs, strategic transaction costs, debt extinguishment charges, insurance settlement gain, gains and losses on the Company's investments, stock compensation costs and other income. Adjusted net income adjusts interest expense to reflect pro forma interest from the Company's term loan facility under the Company's current capital structure after giving effect to the completing of the refinancing transactions in connection with the Separation, and it includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations. Adjusted EBITDA represents operating income from continuing operations excluding restructuring and other charges, MDR and other costs, strategic transaction costs, stock-based compensation costs, depreciation and amortization, amortization of acquired intangibles, insurance settlement gain, and inventory step up costs. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Organic sales growth excludes the impact of acquisitions and foreign exchange rate fluctuations. Sales per day growth includes the same adjustments as Organic sales growth and adjusts for the number of selling days in the period. These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this presentation. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.

Q1 2023 Highlights




- **Achieved strong organic growth of 9%**
 - 19% organic growth in Recon
 - 4% organic growth in P&R
- **Expanded adjusted EBITDA margins 120 basis points**
 - Inflation stabilizing, mix effect from strong Recon sales
- **Continued strategic M&A execution**
 - Strengthening Foot & Ankle franchise with Novastep® acquisition
 - Strong momentum scaling recent acquisitions

Strong start toward 2023 strategic growth objectives

Q1 Reconstructive Segment Sales Performance

Reconstructive Q1 Sales

Growth: Organic sales +19%; total reported sales +19%




- **Strong Double-digit US growth**
 - Knees & hips organic growth of 22%
 - Extremities organic growth of 14%, led by shoulder
- **International organic growth >20%, led by hip/knee**
 - Strong underlying market
 - Brand and presence expanding in Europe
 - Early traction on cross-selling efforts
- **Continued innovation**
 - EMPOWR Revision Knee™ commercialization
 - Altivate® Anatomic Augmented Glenoid ramp

Demonstrating sustainable DD growth and strong share gain

Strengthening Position in Fast-Growing F&A Market

- enovis offerings
- Recently signed M&A



1 Novastep® (MIS Bunion)

- Strengthens position in \$0.9B bunion segment, the largest and fastest-growing part of the F&A market
- CE marked forefoot and midfoot implants and strong OUS channel furthers global expansion strategy

2 Seal (External Fixation)


- Leading external fixation product line
- Complements existing offerings, strengthens channel position

Building a leading Foot & Ankle platform

Q1 Prevention & Recovery Segment Sales Performance


P&R Q1 Sales

Growth: Organic sales +4%; total reported 2.4%



- **Organic growth of 4%**
 - Volume rebounded from slow Q4

Sales Per Day Growth (%)



- **Supply chain continues to stabilize**
- **Strong pipeline of 2023 bracing launches**

P&R returned to healthy growth in Q1

P&L Performance

<i>millions</i>	<u>Q1 2022</u>	<u>Q1 2023</u>
Net Sales	\$375	\$406
Adj. Gross Profit Margin	\$212 56.3%	\$235 58.0%
Adj. EBITDA Margin	\$48 12.7%	\$56 13.9%
Adj. EPS	\$0.37	\$0.44

- HSD organic sales growth of +9%, led by Recon
- +170 bps of gross margin improvement, driven by mix and progress on price vs. cost
- Increased investments in R&D to support innovation agenda
- +120 bps of aEBITDA margin expansion and +19% aEPS improvement year over year driven by strong, profitable growth


Strong growth and margin improvement in Q1

Full Year 2023 Outlook

	February	May	Comments
Organic Sales Growth	5-6% (cc)	6-7% (cc)	<ul style="list-style-type: none"> Increased growth and profit outlook Recent M&A activity is included in outlook: <ul style="list-style-type: none"> \$25-30mm annualized revenue Small profit dilution in '23 Interest expense from debt Assumes latest FX rates hold
aEBITDA	\$255-\$265mm	\$259-\$267mm	
Depreciation	~\$85mm	~\$85mm	
Interest Expense	~\$23mm	~\$23mm	
Effective Tax Rate	~20%	~20%	
aEPS	\$2.15-\$2.30	\$2.18-\$2.32	

Improving sales, profit and earnings guidance based on strong Q1 performance

Summary



- Strong performance to start the year, increased FY guidance
- High-single-digit growth in Q1, further momentum for creating a HSD growth engine fueled by innovation
- Strong margin improvement in Q1, clear path for sustainable >50bps annual improvement through mix, productivity and scale
- Expanding fast-growing Foot & Ankle business through M&A, robust acquisition funnel and ample capital to accelerate growth and compound value

Appendix



enovis™

Creating Better Together™

QTD Enovis Sales Bridge

Enovis Corporation
Reconciliation of GAAP to non-GAAP Financial Measures
Change in Sales
Dollars in millions
(Unaudited)

	Net Sales					
	Prevention and Recovery		Reconstructive		Total Enovis	
	\$	Change %	\$	Change %	\$	Change %
For the three months ended April 1, 2022	\$ 244.8		\$ 130.6		\$ 375.5	
<i>Components of Change:</i>						
Existing businesses ⁽¹⁾	10.1	4.1 %	25.1	19.2 %	35.2	9.4 %
Acquisitions ⁽²⁾	—	— %	1.1	0.8 %	1.1	0.3 %
Foreign currency translation ⁽³⁾	(4.2)	(1.7)%	(1.4)	(1.1)%	(5.6)	(1.5)%
	5.9	2.4 %	24.8	19.0 %	30.7	8.2 %
For the three months ended March 31, 2023	<u>\$ 250.8</u>		<u>\$ 155.4</u>		<u>\$ 406.2</u>	

⁽¹⁾ Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price, product mix and volume.

⁽²⁾ Represents the incremental sales as a result of acquisitions closed subsequent to the beginning of the prior year period.

⁽³⁾ Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.

QTD Enovis aEPS Reconciliation

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions, except per share data
(Unaudited)

	Three Months Ended	
	March 31, 2023	April 1, 2022
Adjusted Net Income and Adjusted Net Income Per Share		
Net loss from continuing operations attributable to Enovis Corporation ⁽¹⁾ (GAAP)	\$ (23.0)	\$ (38.3)
Restructuring and other charges - pretax ⁽²⁾	2.9	3.0
MDR and other costs - pretax ⁽³⁾	7.8	2.6
Amortization of acquired intangibles - pretax	32.0	30.8
Inventory step-up - pretax	0.1	5.1
Strategic transaction costs - pretax ⁽⁴⁾	11.6	11.7
Pro forma interest expense adjustment ⁽⁵⁾	—	6.1
Stock-based compensation	6.9	6.7
Other income	(0.7)	—
Tax adjustment ⁽⁶⁾	(13.6)	(7.4)
Adjusted net income from continuing operations (non-GAAP)	<u>\$ 24.1</u>	<u>\$ 20.2</u>
Adjusted net income margin from continuing operations	5.9 %	5.4 %
Weighted-average shares outstanding - diluted (in thousands)	54,835	54,409
Adjusted net income per share - diluted from continuing operations (non-GAAP)	\$ 0.44	\$ 0.37
Net loss per share - diluted from continuing operations (GAAP)	\$ (0.42)	\$ (0.71)

⁽¹⁾ Net loss from continuing operations attributable to Enovis Corporation for the respective periods is calculated using Net loss from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of \$0.2 million and \$0.3 million for the three months ended March 31, 2023 and April 1, 2022, respectively.

⁽²⁾ Restructuring and other charges includes \$0.3 million and \$0.5 million of expense classified as Cost of sales on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and April 1, 2022, respectively.

⁽³⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

⁽⁴⁾ Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.

⁽⁵⁾ Adjusts interest expense to reflect pro forma interest from the Company's term loan facility after giving effect to the completion of the refinancing transactions in connection with the Separation.

⁽⁶⁾ The effective tax rates used to calculate adjusted net income and adjusted net income per share were 21.0% and 27.4% for the three months ended March 31, 2023 and April 1, 2022, respectively.

QTD Enovis aEBITDA Reconciliation

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)

	Three Months Ended	
	March 31, 2023	April 1, 2022
	(Dollars in millions)	
Net loss from continuing operations (GAAP)	\$ (22.8)	\$ (38.1)
Income tax expense (benefit)	(7.1)	0.4
Other income	(0.7)	—
Interest expense, net	5.7	7.1
Operating loss (GAAP)	(25.0)	(30.6)
Adjusted to add:		
Restructuring and other charges ⁽¹⁾	2.9	3.0
MDR and other costs ⁽²⁾	7.8	2.6
Strategic transaction costs ⁽³⁾	11.6	11.7
Stock-based compensation	6.9	6.7
Depreciation and other amortization	20.0	18.5
Amortization of acquired intangibles	32.0	30.8
Inventory step-up	0.1	5.1
Adjusted EBITDA (non-GAAP)	<u>\$ 56.4</u>	<u>\$ 47.7</u>
Adjusted EBITDA margin (non-GAAP)	<u>13.9 %</u>	<u>12.7 %</u>

⁽¹⁾ Restructuring and other charges includes \$0.3 million and \$0.5 million of expense classified as Cost of sales on our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and April 1, 2022, respectively.

⁽²⁾ Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.

⁽³⁾ Strategic transaction costs includes costs related to the Separation and certain transaction and integration costs related to recent acquisitions.

Q1'23 GAAP to Adjusted Non-GAAP Financial Measures

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions

	Enovis Continuing Operations	Acquisition- Related Non-Cash Adjustments^a	Restructuring & Other Adjustments^b	Other Adjustments^c	Income Tax Adjustment^d	Adjusted
Net sales	\$ 406.2	\$ -	\$ -	\$ -	\$ -	\$ 406.2
Cost of goods sold	171.1	(0.1)	(0.3)	-	-	170.7
Gross profit	235.1	0.1	0.3	-	-	235.5
<i>Gross margin</i>	<i>57.9%</i>					<i>58.0%</i>
Selling, general and administrative expense	207.2	-	-	(26.3)	-	180.8
Research and development expense	18.2	-	-	-	-	18.2
Amortization of acquired intangibles	32.0	(32.0)	-	-	-	-
Restructuring and other charges	2.6	-	(2.6)	-	-	-
Operating (loss) income	(25.0)	32.2	2.9	26.3	-	36.5
Interest expense, net	5.7	-	-	-	-	5.7
Other income	(0.7)	-	-	0.7	-	-
(Loss) income before taxes	(30.0)	32.2	2.9	25.7	-	30.8
Income tax (benefit) expense	(7.1)	-	-	-	13.6	6.5
Less: NCI income, net of taxes	0.2	-	-	-	-	0.2
Net (loss) income attributable to Enovis	<u>\$ (23.0)</u>	<u>\$ 32.2</u>	<u>\$ 2.9</u>	<u>\$ 25.7</u>	<u>\$ (13.6)</u>	<u>\$ 24.1</u>

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$11.6, stock-based compensation expense of \$6.9 and MDR & other costs of \$7.8.

^d The effective tax rate used to calculate adjusted net income and adjusted net income per share was 21.0%.

Q1'22 GAAP to Adjusted Non-GAAP Financial Measures

Enovis Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions

	Enovis Continuing Operations	Acquisition- Related Non-Cash Adjustments ^a	Restructuring & Other Adjustments ^b	Other Adjustments ^c	Debt Adjustments ^d	Income Tax Adjustment ^e	Adjusted
Net sales	\$ 375.5	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 375.5
Cost of goods sold	169.6	(5.1)	(0.5)	-	-	-	163.9
Gross profit	205.9	5.1	0.5	-	-	-	211.5
<i>Gross margin</i>	<i>54.8%</i>						<i>56.3%</i>
Selling, general and administrative expense	188.5	-	-	(21.0)	-	-	167.4
Research and development expense	14.8	-	-	-	-	-	14.8
Amortization of acquired intangibles	30.8	(30.8)	-	-	-	-	-
Restructuring and other charges	2.4	-	(2.4)	-	-	-	-
Operating (loss) income	(30.6)	35.9	3.0	21.0	-	-	29.2
Interest expense, net	7.1	-	-	-	(6.1)	-	1.0
(Loss) income before taxes	(37.7)	35.9	3.0	21.0	6.1	-	28.2
Income tax expense	0.4	-	-	-	-	7.4	7.7
Less: NCI income, net of taxes	0.3	-	-	-	-	-	0.3
Net (loss) income attributable to Enovis	\$ (38.3)	\$ 35.9	\$ 3.0	\$ 21.0	\$ 6.1	\$ (7.4)	\$ 20.2

^a Removes impact of amortization of acquired intangibles and fair value charges of acquired inventory.

^b Removes impact of restructuring and other charges.

^c Removes impact of strategic transaction costs of \$11.7, stock-based compensation expense of \$6.7 and MDR & other costs of \$2.6.

^d Adjusts interest expense to \$1.0 to reflect a deleveraged debt structure and removes impact of debt extinguishment charges.

^e The effective tax rate used to calculate adjusted net income and adjusted net income per share was 27.4%.



Creating Better Together™